Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Axsome Therapeutics' AXS-12 (Reboxetine) Achieved The Primary Endpoint And Significantly Reduced The Frequency Of Cataplexy Attacks As Compared To Placebo In Narcolepsy Patients In SYMPHONY Phase 3 Trial

Author: Benzinga Newsdesk | March 25, 2024 06:32am

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo. 

Posted In: AXSM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist